TrialNature communications2023

Safety and immunogenicity of Ad5-nCoV immunization after three-dose priming with inactivated SARS-CoV-2 vaccine in Chinese adults.

Hangjie Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.